Αρχική World News Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative Advanced... World News Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer Από Ogkologos - 28 Νοεμβρίου, 2024 996 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the INAVO120 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Deaths from Metastatic Melanoma Drop Substantially in the United States 21 Απριλίου, 2020 FDA Grants Accelerated Approval to Talquetamab-tgvs for Relapsed or Refractory Multiple... 15 Σεπτεμβρίου, 2023 Can Using a Microwave Cause Cancer? 25 Μαρτίου, 2021 Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with... 22 Νοεμβρίου, 2024 Φόρτωση περισσοτέρων HOT NEWS A Short-Course of Induction Chemotherapy Followed by Chemoradiotherapy Significantly Improves Survival... ESMO Open: First Official Impact Factor of 5.329 Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among... ¿Vivir cerca de líneas eléctricas aumenta mi riesgo de desarrollar cáncer?